Qyuns Therapeutics Co., Ltd. Class H (HK:2509)
:2509
Want to see HK:2509 full AI Analyst Report?
2509 Stock Chart & Stats
HK$28.58
HK$0.02(0.29%)
At close: 4:00 PM EST
HK$28.58
HK$0.02(0.29%)
Day’s Range― - ―
52-Week RangeHK$13.50 - HK$36.50
Previous CloseN/A
Volume3.00K
Average Volume (3M)305.01K
Market Cap
HK$3.54B
Enterprise ValueHK$2.89B
Total Cash (Recent Filing)HK$558.90M
Total Debt (Recent Filing)HK$635.93M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding227,071,600
10 Day Avg. Volume194,489
30 Day Avg. Volume305,010
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)5.43
Price to Sales (P/S)4.80
P/FCF Ratio9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$33.50Price Target Upside17.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.72
Revenue Forecast (FY)HK$550.33M
Bulls Say, Bears Say
Bulls Say
Sharp 2025 Revenue & Profit InflectionA large 2025 revenue increase and high net margin indicate the company reached meaningful commercial scale and improved unit economics. Sustained higher margins would fund R&D and commercialization, strengthen reinvestment capacity and improve long-term cash returns if maintained beyond the isolated year.
Improved Balance Sheet And LeverageMaterial equity growth and a markedly lower debt-to-equity ratio reduce refinancing pressure and enhance solvency. That improvement supports strategic flexibility for investments or M&A and lowers default risk, making the capital structure more resilient over the medium term if earnings remain positive.
Positive Operating And Free Cash FlowStrong cash generation with FCF closely tracking net income shows high earnings quality and conversion. Durable cash flow allows internal funding of growth, R&D and debt reduction without external financing, improving long-term financial independence if the company sustains these levels.
Bears Say
History Of Multi-year VolatilityA multi-year pattern of losses and swings in leverage and cash flow indicates the firm's results have been episodic, raising execution and forecasting risk. This history reduces confidence that the latest positive year represents a permanent structural shift rather than a temporary rebound.
Meaningful Absolute Debt StockDespite ratio improvement, a large absolute debt burden creates ongoing interest and principal obligations that can strain cash in downturns. High nominal debt limits strategic optionality and heightens refinancing and covenant risk over the medium term if cash generation weakens.
Durability Of Margins And Turnaround UnprovenA one-year jump to high margins may reflect discrete events or early-cycle pricing power rather than sustained structural improvement. If revenue growth slows or costs normalize, margins could compress, making the current profitability profile uncertain absent multi-year confirmation.
Qyuns Therapeutics Co., Ltd. Class H News
2509 FAQ
What was Qyuns Therapeutics Co., Ltd. Class H’s price range in the past 12 months?
Qyuns Therapeutics Co., Ltd. Class H lowest stock price was HK$13.50 and its highest was HK$36.50 in the past 12 months.
What is Qyuns Therapeutics Co., Ltd. Class H’s market cap?
Qyuns Therapeutics Co., Ltd. Class H’s market cap is HK$3.54B.
When is Qyuns Therapeutics Co., Ltd. Class H’s upcoming earnings report date?
Qyuns Therapeutics Co., Ltd. Class H’s upcoming earnings report date is Aug 14, 2026 which is in 69 days.
How were Qyuns Therapeutics Co., Ltd. Class H’s earnings last quarter?
Qyuns Therapeutics Co., Ltd. Class H released its earnings results on Mar 27, 2026. The company reported HK$1.69 earnings per share for the quarter, beating the consensus estimate of N/A by HK$1.69.
Is Qyuns Therapeutics Co., Ltd. Class H overvalued?
According to Wall Street analysts Qyuns Therapeutics Co., Ltd. Class H’s price is currently Undervalued.
Does Qyuns Therapeutics Co., Ltd. Class H pay dividends?
Qyuns Therapeutics Co., Ltd. Class H does not currently pay dividends.
What is Qyuns Therapeutics Co., Ltd. Class H’s EPS estimate?
Qyuns Therapeutics Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qyuns Therapeutics Co., Ltd. Class H have?
Qyuns Therapeutics Co., Ltd. Class H has 227,071,600 shares outstanding.
What happened to Qyuns Therapeutics Co., Ltd. Class H’s price movement after its last earnings report?
Qyuns Therapeutics Co., Ltd. Class H reported an EPS of HK$1.69 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.485%.
Which hedge fund is a major shareholder of Qyuns Therapeutics Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2509
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Qyuns Therapeutics Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.56%
12-Months-Change
Fundamentals
Return on Equity
-32.00%
Trailing 12-Months
Asset Growth
70.24%
Trailing 12-Months
Company Description
Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. Class H (2509) is a biotechnology company focused on the development of innovative therapies for the treatment of various diseases, particularly in the fields of oncology and autoimmune disorders. The company specializes in research, development, and commercialization of biopharmaceutical products, leveraging cutting-edge technology and scientific research to address unmet medical needs. Qyuns Therapeutics aims to provide novel treatment options through its pipeline of drug candidates, enhancing patient care and outcomes.
2509 Stock 12 Month Forecast
Average Price Target
HK$33.50
▲(17.21% Upside)
Technical Analysis
Antengene Corporation Limited
―
Genor Biopharma Holdings Limited
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―
Options Prices
Currently, No data available
---